MétaCan
Menu
← Back to cohort
Record W4409625223 · doi:10.1158/1538-7445.am2025-243

Abstract 243: FLT4, a novel regulator of renal cell carcinoma progression

2025· article· en· W4409625223 on OpenAlexaff
Djazia Haferssas, Nathalie Henley, Jonatan Barrera Chimal, Casimiro Gerarduzzi

Bibliographic record

VenueCancer Research · 2025
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCancer, Hypoxia, and Metabolism
Canadian institutionsUniversité de Montréal
Fundersnot available
KeywordsRegulatorRenal cell carcinomaCancer researchMedicineClear cell renal cell carcinomaBiologyInternal medicinePathologyGeneticsGene

Abstract

fetched live from OpenAlex

Abstract Background: Clear Cell Renal Cell Carcinoma (ccRCC) is one of the ten most frequently diagnosed malignancies worldwide and constitutes 2-3% of all adult cancers. Disruption of p53 function, a critical tumor suppressor, plays a pivotal role in cancer development and resistance to chemotherapy. While p53 gene mutations are rare in ccRCC, these tumors often resist DNA-damage- based therapies, suggesting alternative mechanisms suppressing wild-type p53 in ccRCC. Therefore, reactivating this pathway represents a potential therapeutic strategy. p53 is tightly regulated by MDM2 and MDMX which are frequently elevated in ccRCC patients. However, the molecular mechanisms underlying MDM2/MDMX-mediated p53 regulation in ccRCC remain unclear. Our study identified the Receptor Tyrosine Kinase FLT4 as a novel regulator of MDM2/MDMX and p53 activity. Notably, both FLT4 and its ligand, VEGFC, are overexpressed in ccRCC patients. Hypothesis: We propose that FLT4 activation increases the stability of the MDM2/MDMX complex, resulting in p53 inactivation and promoting ccRCC tumorigenesis. Methods: 1) We analyzed Bulk and single cell RNAseq data of ccRCC patients from the Cancer Genome Atlas (TCGA) to assess the expression of FLT4 and VEGFC. 2) The ccRCC cell lines ACHN and Caki-2 were used for in vitro experiments, including VEGFC treatment for functional assays (proliferation, migration, and survival) and MDM2/MDMX/p53 protein analysis. 3) ACHN and Caki-2 cells were transduced with Luciferase and FLT4 and injected into immunodeficient NOD/SCID mice to study tumor development and metastasis using In vivo Imaging System (IVIS). Results: FLT4 and VEGFC are overexpressed in ccRCC patients and correlate with cancer progression and poor survival. In addition, FLT4 activation promotes proliferation and migration both in vitro and in vivo and reduces the chemosensitivity of ccRCC cells mainly through the modulation of p53 levels. Mechanistically, FLT4 activation decreases p53 stability and activity by increasing MDM2/MDMX levels through post-translational modifications. Conclusion: Aberrant FLT4 signaling drives ccRCC progression by suppressing p53 through the upregulation of its negative regulators MDM2 and MDMX. These findings highlight FLT4 as a potential target for restoring p53 activity and improving ccRCC outcomes. Citation Format: Djazia Haferssas, Nathalie Henley, Jonatan Barrera Chimal, Casimiro Gerarduzzi. FLT4, a novel regulator of renal cell carcinoma progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 243.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Other · Consensus signal: none
Teacher disagreement score0.003
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.035
GPT teacher head0.379
Teacher spread0.344 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreOther

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueCancer Research→Same topicCancer, Hypoxia, and Metabolism→French-language works237,207→